Literature DB >> 29990495

BRN 2 Invade.

Gaurav Pathria1, Ze'ev A Ronai2.   

Abstract

One of the remaining challenges in treating melanoma is its strong propensity to metastasize. Thus, there is considerable interest in understanding the alterations that drive progression of the disease. In this issue of Cancer Cell, Shain et al. and Zheng et al. provide insights implicating p16INK4A in melanoma invasiveness.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29990495      PMCID： PMC6311383          DOI： 10.1016/j.ccell.2018.06.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  A landscape of driver mutations in melanoma.

Authors:  Eran Hodis; Ian R Watson; Gregory V Kryukov; Stefan T Arold; Marcin Imielinski; Jean-Philippe Theurillat; Elizabeth Nickerson; Daniel Auclair; Liren Li; Chelsea Place; Daniel Dicara; Alex H Ramos; Michael S Lawrence; Kristian Cibulskis; Andrey Sivachenko; Douglas Voet; Gordon Saksena; Nicolas Stransky; Robert C Onofrio; Wendy Winckler; Kristin Ardlie; Nikhil Wagle; Jennifer Wargo; Kelly Chong; Donald L Morton; Katherine Stemke-Hale; Guo Chen; Michael Noble; Matthew Meyerson; John E Ladbury; Michael A Davies; Jeffrey E Gershenwald; Stephan N Wagner; Dave S B Hoon; Dirk Schadendorf; Eric S Lander; Stacey B Gabriel; Gad Getz; Levi A Garraway; Lynda Chin
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

Review 3.  Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer.

Authors:  Junan Li; Ming Jye Poi; Ming-Daw Tsai
Journal:  Biochemistry       Date:  2011-06-06       Impact factor: 3.162

Review 4.  BRN2, a POUerful driver of melanoma phenotype switching and metastasis.

Authors:  Mitchell E Fane; Yash Chhabra; Aaron G Smith; Richard A Sturm
Journal:  Pigment Cell Melanoma Res       Date:  2018-06-05       Impact factor: 4.693

Review 5.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

6.  Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.

Authors:  Jane Goodall; Suzanne Carreira; Laurence Denat; Dominique Kobi; Irwin Davidson; Paolo Nuciforo; Richard A Sturm; Lionel Larue; Colin R Goding
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

Review 7.  The INK4a/ARF locus and melanoma.

Authors:  E Sharpless; Lynda Chin
Journal:  Oncogene       Date:  2003-05-19       Impact factor: 9.867

8.  Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination.

Authors:  Sophie Pinner; Peter Jordan; Kirsty Sharrock; Laura Bazley; Lucy Collinson; Richard Marais; Elise Bonvin; Colin Goding; Erik Sahai
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

9.  Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.

Authors:  Hanlin Zeng; Aparna Jorapur; A Hunter Shain; Ursula E Lang; Rodrigo Torres; Yuntian Zhang; Andrew S McNeal; Thomas Botton; Jue Lin; Matthew Donne; Ingmar N Bastian; Richard Yu; Jeffrey P North; Laura Pincus; Beth S Ruben; Nancy M Joseph; Iwei Yeh; Boris C Bastian; Robert L Judson
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743

10.  Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.

Authors:  A Hunter Shain; Nancy M Joseph; Richard Yu; Jamal Benhamida; Shanshan Liu; Tarl Prow; Beth Ruben; Jeffrey North; Laura Pincus; Iwei Yeh; Robert Judson; Boris C Bastian
Journal:  Cancer Cell       Date:  2018-07-09       Impact factor: 31.743
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.